Anti-Irisin (FNDC5), clone 2K10 ZooM

Application

Anti-Irisin (FNDC5), clone 2K10 ZooMAb, Cat. No. ZRB1015, is a recombinant Rabbit monoclonal antibody that specifically targets Irisin (FNDC5) and is tested for use in Affinity Binding Assay, Immunocytochemistry, Immunohistochemistry (Paraffin), and Western Blotting.

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected Irisin (FNDC5) in HepG2 cell lysate.Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected Irisin (FNDC5) in human skeletal muscle cells.Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected Irisin (FNDC5) in human skeletal muscle tissue sections.Affinity Binding Assay: A representative lot of this antibody bound FNDC5 peptide with a KD of 4.5 x 10-9 in an affinity binding assay.Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.Learn more about ZooMAb here.

Immunogen

KLH-conjugated linear peptide corresponding to 21 amino acids from the Irisin region of the extracellular domain of human Fibronectin type III domain-containing protein 5 (FNDC5).

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Physical form

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

Reconstitution

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Specificity

Clone 2K10 is a ZooMAb rabbit recombinant monoclonal antibody that specifically detects Fibronectin type III domain-containing protein 5 (FNDC5). It targets and epitope within the Irisin region.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Target description

Fibronectin type III domain-containing protein 5 (UniProt: Q8NAU1; also known as Fibronectin type III repeat-containing protein 2; FNDC5) is encoded by the FNDC5 (also known as FRCP2) gene (Gene ID: 252995) in human. FNDC5 is a single-pass type I membrane protein that is synthesized with a signal peptide (aa 1-31), which is subsequently cleaved off to produce the mature protein that contains an extracellular domain (aa 32-152), a transmembrane domain (aa 153-173), and a cytoplasmic domain (aa 174-212). The mature FNDC5 can be further cleaved into Irisin (aa 32-143). FNDC5/Irisin is widely expressed and is considered to be a thermogenic, exercise-induced chemokine that is involved in the browning of adipose tissue. It is released mainly by the white subcutaneous adipose tissue and plays a regulatory role in conversion of white fat to brown fat and has a potential in curbing fat accumulation. Its levels are shown to be upregulated by exercise and it can be detected in the blood of individuals following endurance exercise. It has also been associated with reduction of pro-inflammatory cytokines while promoting secretion of anti-inflammatory cytokines in adipose tissue. Irisin is reported to facilitate glucose uptake by skeletal muscles and improve hepatic glucose and lipid metabolism thereby causing a positive effect on hyperlipidemia and hyperglycemia caused by obesity and metabolic syndrome. Lower levels of Irisin are reported in diabetic patients compared to normal subjects. Irisin stimulation of glucose uptake in muscle tissue involves the activation of AMPK pathway. (Ref.: Arhire LI., et al. (2019). Front Endocrinol.10; 524; Zhang, Y., et al. (2014). Diabetes. 63(2); 514-525).